Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported the earnings of $-0.1/Share in the last quarter. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 9.1%.
Many analysts are providing their Estimated Earnings analysis for Aurinia Pharmaceuticals Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.14/share. These analysts have also projected a Low Estimate of $-0.16/share and a High Estimate of $-0.12/share.
In case of Revenue Estimates, 4 analysts have provided their consensus Average Revenue Estimates for Aurinia Pharmaceuticals Inc. as 60 Million. According to these analysts, the Low Revenue Estimate for Aurinia Pharmaceuticals Inc. is 30 Million and the High Revenue Estimate is 100 Million. The company had Year Ago Sales of 57 Million.
Some buy side analysts are also providing their Analysis on Aurinia Pharmaceuticals Inc., where 2 analysts have rated the stock as Strong buy, 2 analysts have given a Buy signal, 0 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. 5 Analysts reported that the Price Target for Aurinia Pharmaceuticals Inc. might touch $10 high while the Average Price Target and Low price Target is $8.9 and $7 respectively.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Aurinia Pharmaceuticals Inc. got Initiated on 30-Jun-16 where investment firm H.C. Wainwright Initiated the stock to Buy.
Aurinia Pharmaceuticals Inc. closed its last trading session at $4.36 with the loss of -5.28%. The Market Capitalization of the company stands at 0. The Company has 52-week high of $5.69 and 52-week low of $1.42. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 20.25% where SMA50 and SMA200 are 46.96% and 52.43% respectively. The Company Touched its 52-Week High on Oct 6, 2016 and 52-Week Low on Jan 15, 2016.
The Relative Volume of the company is 0.51 and Average Volume (3 months) is 2.63 million. Aurinia Pharmaceuticals Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of 0%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is 0%.
While looking at the Stock’s Performance, Aurinia Pharmaceuticals Inc. currently shows a Weekly Performance of -7.61%, where Monthly Performance is 99.52%, Quarterly performance is 36.75%, 6 Months performance is 39.53% and yearly performance percentage is 33.23%. Year to Date performance value (YTD perf) value is 67.21%. The Stock currently has a Weekly Volatility of 12.47% and Monthly Volatility of 10.85%.